The effects of remdesivir on mortality and the requirement for mechanical ventilation in patients with COVID-19: a systematic review stratified by disease severity
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The effectiveness of remdesivir treatment in reducing mortality and the requirement for mechanical ventilation (MV) remains uncertain, as randomized controlled trials (RCTs) have produced conflicting results. Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and other data resources to find RCTs published prior to April 10, 2023. The selection of studies, assessment of risk of bias, and meta-analysis were conducted according to PRISMA guidelines. The primary outcomes were all-cause mortality and the need to initiate MV. Results: A total of 5,068 articles were screened, from eight RCTs comprising 11,945 patients. The meta-analysis found that, compared to standard care or placebo, remdesivir treatment provided no significant all-cause mortality benefit (pooled risk ratio [RR], 0.93; 95% confidence interval [CI], 0.85–1.02; 8 studies; high certainty evidence), while subgroup analyses revealed a trend towards reduced mortality among patients requiring oxygen but not MV (pooled RR, 0.88; 95% CI, 0.77–1.00; 6 studies; I2 = 4%). The need to initiate MV (pooled RR, 0.74; 95% CI, 0.59–0.94; 7 studies; moderate certainty evidence) in remdesivir-treated patients was also reduced compared to controls. Remdesivir significantly increased clinical improvement and discharge and significantly reduced serious adverse events. Conclusions: In this systematic review and meta-analysis of RCTs, it was found that remdesivir treatment did not show a substantial decrease in the risk of mortality. However, it was linked to a reduction in the necessity for additional ventilatory support, suggesting remdesivir could be beneficial for COVID-19 patients, particularly those who are not on MV.
Abstract
Background/Aims: The effectiveness of remdesivir treatment in reducing mortality and the requirement for mechanical ventilation (MV) remains uncertain, as randomized controlled trials (RCTs) have produced conflicting results. Methods: We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and other data resources to find RCTs published prior to April 10, 2023. The selection of studies, assessment of risk of bias, and meta-analysis were conducted according to PRISMA guidelines. The primary outcomes were all-cause mortality and the need to initiate MV. Results: A total of 5,068 articles were screened, from eight RCTs comprising 11,945 patients. The meta-analysis found that, compared to standard care or placebo, remdesivir treatment provided no significant all-cause mortality benefit (pooled risk ratio [RR], 0.93; 95% confidence interval [CI], 0.85–1.02; 8 studies; high certainty evidence), while subgroup analyses revealed a trend towards reduced mortality among patients requiring oxygen but not MV (pooled RR, 0.88; 95% CI, 0.77–1.00; 6 studies; I2 = 4%). The need to initiate MV (pooled RR, 0.74; 95% CI, 0.59–0.94; 7 studies; moderate certainty evidence) in remdesivir-treated patients was also reduced compared to controls. Remdesivir significantly increased clinical improvement and discharge and significantly reduced serious adverse events. Conclusions: In this systematic review and meta-analysis of RCTs, it was found that remdesivir treatment did not show a substantial decrease in the risk of mortality. However, it was linked to a reduction in the necessity for additional ventilatory support, suggesting remdesivir could be beneficial for COVID-19 patients, particularly those who are not on MV.
참고문헌 (19)
- Wang Y, "Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial", Lancet, 395, pp.1569~1578 (2020)
- Beigel JH, "Remdesivir for the Treatment of Covid-19 - Final Report", N Engl J Med, 383, pp.1813~1826 (2020)
- Spinner CD, "Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial", JAMA, 324, pp.1048~1057 (2020)
- Mahajan L, "Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19 : a prospective randomised study", Indian J Anaesth, 65(Suppl 1), pp.S41~S46 (2021)
- Ali K, "Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial", CMAJ, 194, pp.E242~E251 (2022)
- Ader F, "Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial", Lancet Infect Dis, 22, pp.209~221 (2022)
- Joo EJ, "Clinical and virologic effectiveness of remdesivir treatment for severe coronavirus disease 2019(COVID-19)in Korea : a nationwide multicenter retrospective cohort study", J Korean Med Sci, 36, pp.e83~ (2021)
- WHO Solidarity Trial Consortium, "Remdesivir and three other drugs for hospitalised patients with COVID-19 : final results of the WHO Solidarity randomised trial and updated meta-analyses", Lancet, 399, pp.1941~1953 (2022)
- Gottlieb RL, "Early remdesivir to prevent progression to severe Covid-19 in outpatients", N Engl J Med, 386, pp.305~315 (2022)
- Cumpston M, "Updated guidance for trusted systematic reviews : a new edition of the Cochrane Handbook for Systematic Reviews of Interventions", Cochrane Database Syst Rev, 10, pp.ED000142~ (2019)
- Page MJ, "The PRISMA 2020statement: an updated guideline for reporting systematic reviews", Rev Esp Cardiol (Engl Ed), 74, pp.790~799 (2021)
- Kim SB, "Revised Korean Society of Infectious Diseases", National Evidence-based Healthcarea Collaborating Agency guidelines on the treatment of patients with COVID-19, 2021, pp.53, 166~219
- Guyatt GH, "GRADE guidelines : 13. Preparing summary of findings tables and evidence profiles-continuous outcomes", J Clin Epidemiol, 66, pp.173~183 (2013)
- Lee TC, "Remdesivir for the treatment of COVID-19 : a systematic review and meta-analysis", Clin Microbiol Infect, 28, pp.1203~1210 (2022)
- Beckerman R, "Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen : a targeted literature review and meta-analysis", Sci Rep, 12, pp.9622~ (2022)
- Grundeis F, "Remdesivir for the treatment of COVID-19", Cochrane Database Syst Rev, 1, pp.CD014962~ (2023)
- Amstutz A, "Effects of remdesivir in patients hospitalised with COVID-19 : a systematic review and individual patient data meta-analysis of randomised controlled trials", Lancet Respir Med, 11, pp.453~464 (2023)
- Ferrer M, "Severe community-acquired pneumonia : characteristics and prognostic factors in ventilated and non-ventilated patients", PLoS One, 13, pp.e0191721~ (2018)
- Klompas M, "Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals : 2022 Update", Infect Control Hosp Epidemiol, 43, pp.687~713 (2022)